Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

• DOI: 10.1007/s11523-020-00753-7
• Publication Date: 2020-10-22T10:02:46Z
• Authors: Julie G. Fisher; David Tait; Elizabeth Garrett...; Susan Halabi; Pam K. Mangat; Julian C. Schink; Ricardo H. Alvarez; Dan Veljovich; Timothy L. Cannon; Pamela A. Crilley; Theodore Pollock; Carmen J. Calfa; Tareq Al Baghdadi; Ramya Thota; Nicole Fleming; Jared A. Cotta; Andrew L. Rygiel; Sasha L. Warren; Richard L. Schilsky
• Keywords: Male; Proto-Oncogene Proteins B-raf; Lung Neoplasms; Cetuximab; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Middle Aged; 3. Good health; 03 medical and health sciences; Antineoplastic Agents, Immunological; 0302 clinical medicine; Carcinoma, Non-Small-Cell Lung; Humans; Female; Registries; Aged

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study, a phase II basket study, evaluates anti-tumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known as drug targets.With no known genomic targets predictive of sensitivity to cetuximab, cetuximab was evaluated in patients with breast cancer (BC), non-small cell lung cancer (NSCLC), and ovarian cancer (OC), without KRAS, NRAS, or BRAF mutations.Eligible patients with advanced BC, NSCLC, and OC received a cetuximab loading dose, then weekly infusions (250 mg/m2 over 60 min). A Simon two-stage design, requiring ten patients in stage I, was employed per each disease-specific cohort. The primary endpoint was disease control (objective response or stable disease for at least 16 weeks). If two or more patients in stage I achieved disease control, the cohort would enroll 18 more patients in stage II. Power and alpha of the design are 85% and 10%, respectively. Secondary endpoints included progression-free survival, overall survival, and safety.Patients with BC (n = 10), NSCLC (n = 10), and OC (n = 29) were enrolled between June 2016 and September 2018. No objective responses or stable disease for at least 16 weeks were observed in the BC and NSCLC cohorts. No objective responses and four patients with stable disease for at least 16 weeks were observed in the OC cohort. Six of 49 patients reported grade 3 or higher adverse events or serious adverse events at least possibly related to cetuximab.Cetuximab does not have clinical activity in patients with advanced BC, NSCLC, and OC without KRAS, NRAS, or BRAF mutations.NCT02693535 (26 February, 2016).